EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease

The therapeutic targeting of prostanoid subtype receptors may slow the development of chronic kidney disease (CKD) through mechanisms that are distinct from those of upstream COX inhibition. Here, employing multiple experimental models of CKD, we studied the effects of inhibition of the EP4 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieme, Karina, Majumder, Syamantak, Brijmohan, Angela S., Batchu, Sri N., Bowskill, Bridgit B., Alghamdi, Tamadher A., Advani, Suzanne L., Kabir, M. Golam, Liu, Youan, Advani, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469816/
https://www.ncbi.nlm.nih.gov/pubmed/28611444
http://dx.doi.org/10.1038/s41598-017-03237-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469816/
https://www.ncbi.nlm.nih.gov/pubmed/28611444
http://dx.doi.org/10.1038/s41598-017-03237-3

Ejemplares similares